
Title:
Acetylcysteine
Text:
Medication


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}AcetylcysteineClinical dataPronunciation/əˌsiːtəlˈsɪstiːn/ and similar (/əˌsɛtəl-, ˌæsɪtəl-, -tiːn/) Trade namesAcetadote, Fluimucil, Mucomyst, othersOther namesN-acetylcysteine; N-acetyl-L-cysteine; NALC; NACAHFS/Drugs.comMonographLicense data
US DailyMed: Acetylcysteine
US FDA: Acetylcysteine
Pregnancycategory
AU: B2

Routes ofadministrationBy mouth, injection, inhalationATC codeR05CB01 (WHO) S01XA08 (WHO) V03AB23 (WHO)Legal statusLegal status
AU: S2 (Pharmacy medicine) 
BR: OTC (Over the counter) (by mouth, IV, inhalation)
US: OTC (by mouth), Rx-only (IV, inhalation)
Pharmacokinetic dataBioavailability10% (Oral)[1]Protein binding50 to 83%[2]MetabolismLiver[2]Elimination half-life5.6 hours[3]ExcretionRenal (30%),[2] faecal (3%)Identifiers
IUPAC name
(2R)-2-acetamido-3-sulfanylpropanoic acid[4]
CAS Number616-91-1 YPubChem CID12035DrugBankDB06151 YChemSpider11540 YUNIIWYQ7N0BPYCKEGGD00221 YChEBICHEBI:28939 YChEMBLChEMBL600 YCompTox Dashboard (EPA)DTXSID5020021 ECHA InfoCard100.009.545 Chemical and physical dataFormulaC5H9NO3SMolar mass163.19 g·mol−13D model (JSmol)Interactive imageSpecific rotation+5° (c = 3% in water)[5]Melting point109 to 110 °C (228 to 230 °F) [5]
SMILES
C/C(=N/[C@@H](CS)C(=O)O)/O

InChI
InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1 YKey:PWKSKIMOESPYIA-BYPYZUCNSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Acetylcysteine, also known as N-acetylcysteine (NAC), is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with chronic bronchopulmonary disorders like pneumonia and bronchitis.[2] It has been used to treat lactobezoar in infants. It can be taken intravenously, by mouth, or inhaled as a mist.[2] Some people use it as a dietary supplement.[6][7]
Common side effects include nausea and vomiting when taken by mouth.[2] The skin may occasionally become red and itchy with any route of administration.[2] A non-immune type of anaphylaxis may also occur.[2] It appears to be safe in pregnancy.[2] For paracetamol overdose, it works by increasing the level of glutathione, an antioxidant that can neutralise the toxic breakdown products of paracetamol.[2] When inhaled, it acts as a mucolytic by decreasing the thickness of mucus.[8]
Acetylcysteine was initially patented in 1960 and came into medical use in 1968.[9][10] It is on the World Health Organization's List of Essential Medicines.[11] It is available as a generic medication and is inexpensive.[12]

Contents

1 Uses

1.1 Paracetamol overdose
1.2 Lungs
1.3 Kidney and bladder
1.4 Psychiatry

1.4.1 Bipolar disorder
1.4.2 Addiction


1.5 Microbiological use
1.6 Other uses


2 Side effects
3 Pharmacology

3.1 Pharmacodynamics
3.2 Pharmacokinetics


4 Chemistry
5 Dosage forms
6 Society and culture
7 Research

7.1 Psychiatry

7.1.1 Bipolar disorder


7.2 COVID-19


8 References
9 External links



Uses[edit]
Paracetamol overdose[edit]
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}Main article: Paracetamol poisoning
Intravenous and oral formulations of acetylcysteine are available for the treatment of paracetamol (acetaminophen) overdose.[13] When paracetamol is taken in large quantities, a minor metabolite called N-acetyl-p-benzoquinone imine (NAPQI) accumulates within the body. It is normally conjugated by glutathione, but when taken in excess, the body's glutathione reserves are not sufficient to deactivate the toxic NAPQI. This metabolite is then free to react with key hepatic enzymes, thereby damaging liver cells. This may lead to severe liver damage and even death by acute liver failure.
In the treatment of paracetamol (acetaminophen) overdose, acetylcysteine acts to maintain or replenish depleted glutathione reserves in the liver and enhance non-toxic metabolism of acetaminophen.[14] These actions serve to protect liver cells from NAPQI toxicity. It is most effective in preventing or lessening hepatic injury when administered within 8–10 hours after overdose.[14] Research suggests that the rate of liver toxicity is approximately 3% when acetylcysteine is administered within 10 hours of overdose.[13]
Although IV and oral acetylcysteine are equally effective for this indication, oral administration is generally poorly tolerated due to the higher dosing required to overcome its low oral bioavailability,[15] its foul taste and odour, and a higher incidence of adverse effects when taken by mouth, particularly nausea and vomiting. Prior pharmacokinetic studies of acetylcysteine did not consider acetylation as a reason for the low bioavailability of acetylcysteine.[16] Oral acetylcysteine is identical in bioavailability to cysteine precursors.[16] However, 3% to 6% of people given intravenous acetylcysteine show a severe, anaphylaxis-like allergic reaction, which may include extreme breathing difficulty (due to bronchospasm), a decrease in blood pressure, rash, angioedema, and sometimes also nausea and vomiting.[17] Repeated doses of intravenous acetylcysteine will cause these allergic reactions to progressively worsen in these people.
Several studies have found this anaphylaxis-like reaction to occur more often in people given IV acetylcysteine despite serum levels of paracetamol not high enough to be considered toxic.[18][19][20][21]

Lungs[edit]
Inhaled acetylcysteine has been used for mucolytic ("mucus-dissolving") therapy in addition to other therapies in respiratory conditions with excessive and/or thick mucus production. It is also used post-operatively, as a diagnostic aid, and in tracheotomy care. It may be considered ineffective in cystic fibrosis.[22] A 2013 Cochrane review in cystic fibrosis found no evidence of benefit.[23]
Acetylcysteine is used in the treatment of obstructive lung disease as an adjuvant treatment.[24][25][26]

Kidney and bladder[edit]
Evidence for the benefit of acetylcysteine to prevent radiocontrast induced kidney disease is mixed.[27]
Acetylcysteine has been used for cyclophosphamide-induced haemorrhagic cystitis, although mesna is generally preferred due to the ability of acetylcysteine to diminish the effectiveness of cyclophosphamide.[28]

Psychiatry[edit]
Acetylcysteine has been studied for major psychiatric disorders,[29][30][31][32] including bipolar disorder,[29] major depressive disorder, and schizophrenia.[30][31]
Tentative evidence exists for N-acetylcysteine also in the treatment of Alzheimer's disease, autism, obsessive-compulsive disorder, specific drug addictions (cocaine), drug-induced neuropathy, trichotillomania, excoriation disorder, and a certain form of epilepsy (progressive myoclonic).[30][31][33] Preliminary evidence showed efficacy in anxiety disorder, attention deficit hyperactivity disorder and mild traumatic brain injury although confirmatory studies are required.[33][34][35][36] Tentative evidence also supports use in cannabis use disorder.[37]

Bipolar disorder[edit]
In bipolar disorder, N-acetylcysteine has been repurposed as an augmentation strategy for depressive episodes in light of the possible role of inflammation in the pathogenesis of mood disorders. Nonetheless, meta-analytic evidence shows that add-on N-acetylcysteine was more effective than placebo only in reducing depression scales scores (low quality evidence), without positive effects on response and remission outcomes, limiting its possible role in clinical practice to date.[29]

Addiction[edit]
Evidence to date does not support the efficacy for N-acetylcysteine in treating addictions to gambling, methamphetamine, or nicotine.[33] Based upon limited evidence, NAC appears to normalize glutamate neurotransmission in the nucleus accumbens and other brain structures, in part by upregulating the expression of excitatory amino acid transporter 2 (EAAT2), a.k.a. glutamate transporter 1 (GLT1), in individuals with addiction.[38] While NAC has been demonstrated to modulate glutamate neurotransmission in adult humans who are addicted to cocaine, NAC does not appear to modulate glutamate neurotransmission in healthy adult humans.[38] NAC has been hypothesized to exert beneficial effects through its modulation of glutamate and dopamine neurotransmission as well as its antioxidant properties.[31]

Microbiological use[edit]
Acetylcysteine can be used in Petroff's method i.e. liquefaction and decontamination of sputum, in preparation for recovery of mycobacterium.[39] It also displays significant antiviral activity against the influenza A viruses.[40]
Acetylcysteine has bactericidal properties and breaks down bacterial biofilms of clinically relevant pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Enterobacter cloacae, Staphylococcus epidermidis, and Klebsiella pneumoniae.[41]

Other uses[edit]
Acetylcysteine has been used to complex palladium, to help it dissolve in water. This helps to remove palladium from drugs or precursors synthesized by palladium-catalyzed coupling reactions.[42] N-actelylcysteine can be used to protect the liver.[43]

Side effects[edit]
The most commonly reported adverse effects for IV formulations of acetylcysteine are rash, urticaria, and itchiness.[14] Up to 18% of patients have been reported to experience anaphylaxis reaction, which are defined as rash, 
hypotension, wheezing, and/or shortness of breath.  Lower rates of anaphylactoid reactions have been reported with slower rates of infusion.
Adverse effects for inhalational formulations of acetylcysteine include nausea, vomiting, stomatitis, fever, rhinorrhea, drowsiness, clamminess, chest tightness, and bronchoconstriction. Although infrequent, bronchospasm has been reported to occur unpredictably in some patients.[44]
Adverse effects for oral formulations of acetylcysteine have been reported to include nausea, vomiting, rash, and fever.[44]
Large doses in a mouse model showed that acetylcysteine could potentially cause damage to the heart and lungs.[45] They found that acetylcysteine was metabolized to S-nitroso-N-acetylcysteine (SNOAC), which increased blood pressure in the lungs and right ventricle of the heart (pulmonary artery hypertension) in mice treated with acetylcysteine. The effect was similar to that observed following a 3-week exposure to an oxygen-deprived environment (chronic hypoxia). The authors also found that SNOAC induced a hypoxia-like response in the expression of several important genes both in vitro and in vivo.
The implications of these findings for long-term treatment with acetylcysteine have not yet been investigated. The dose used by Palmer and colleagues was dramatically higher than that used in humans, the equivalent of about 20 grams per day.[45] Nonetheless, positive effects on age-diminished control of respiration (the hypoxic ventilatory response) have been observed previously in human subjects at more moderate doses.[46]
Although N-acetylcysteine prevented liver damage when taken before alcohol, when taken four hours after alcohol it made liver damage worse in a dose-dependent fashion.[47]

Pharmacology[edit]
Pharmacodynamics[edit]
Acetylcysteine serves as a prodrug to L-cysteine, a precursor to the biologic antioxidant glutathione. Hence administration of acetylcysteine replenishes glutathione stores.[48]

Glutathione, along with oxidized glutathione (GSSG) and S-nitrosoglutathione (GSNO), have been found to bind to the glutamate recognition site of the NMDA and AMPA receptors (via their γ-glutamyl moieties), and may be endogenous neuromodulators.[49][50] At millimolar concentrations, they may also modulate the redox state of the NMDA receptor complex.[50] In addition, glutathione has been found to bind to and activate ionotropic receptors that are different from any other excitatory amino acid receptor, and which may constitute glutathione receptors, potentially making it a neurotransmitter.[51] As such, since N-acetylcysteine is a prodrug of glutathione, it may modulate all of the aforementioned receptors as well.
Glutathione also modulates the NMDA receptor by acting at the redox site.[31][52]
L-cysteine also serves as a precursor to cystine, which in turn serves as a substrate for the cystine-glutamate antiporter on astrocytes; hence there is increasing glutamate release into the extracellular space. This glutamate in turn acts on mGluR2/3 receptors, and at higher doses of acetylcysteine, mGluR5.[53][54]
Acetylcysteine also possesses some anti-inflammatory effects possibly via inhibiting NF-κB and modulating cytokine synthesis.[31]

Pharmacokinetics[edit]
Acetylcysteine is extensively liver metabolized, CYP450 minimal, urine excretion is 22-30% with a half-life of 5.6 hours in adults and 11 hours in neonates.

Chemistry[edit]
Acetylcysteine is the N-acetyl derivative of the amino acid L-cysteine, and is a precursor in the formation of the antioxidant glutathione in the body. The thiol (sulfhydryl) group confers antioxidant effects and is able to reduce free radicals.
N-acetyl-L-cysteine is soluble in water and alcohol, and practically insoluble in chloroform and ether.[55]
It is a white to white with light yellow cast powder, and has a pKa of 9.5 at 30 °C.[5]

Dosage forms[edit]
Acetylcysteine is available in different dosage forms for different indications:

Solution for inhalation (Assist, Mucomyst, Mucosil) – inhaled for mucolytic therapy
Intravenous injection (Assist, Parvolex, Acetadote) – treatment of paracetamol/acetaminophen overdose
Nebulized as an inhaled vapor, particularly in the treatment of cystic fibrosis and other acute pulmonary conditions
Oral solution – various indications
Effervescent tablets
Ocular solution - for mucolytic therapy
Tablets - sometimes in a sustained release formula sold as a nutritional supplement
Capsules
The IV injection and inhalation preparations are, in general, prescription only, whereas the oral solution and the effervescent tablets are available over the counter in many countries. Acetylcysteine is available as a health supplement in the United States, typically in capsule form.

Society and culture[edit]
NAC was first studied as a drug in 1963. Amazon removed NAC for sale in the US in 2021, due to claims by the FDA of it being classified as a drug rather than a supplement.[56][57]

Research[edit]
While many antioxidants have been researched to treat a large number of diseases by reducing the negative effect of oxidative stress, acetylcysteine is one of the few that has yielded promising results, and is currently already approved for the treatment of paracetamol overdose.[58]

In mouse mdx models of Duchenne's muscular dystrophy, treatment with 1-2% acetylcysteine in drinking water significantly reduces muscle damage and improves strength.[58]
It is being studied in conditions such as autism, where cysteine and related sulfur amino acids may be depleted due to multifactorial dysfunction of methylation pathways involved in methionine catabolism.[59]
Animal studies have also demonstrated its efficacy in reducing the damage associated with moderate traumatic brain or spinal injury, and also ischaemia-induced brain injury. In particular, it has been demonstrated to reduce neuronal losses and to improve cognitive and neurological outcomes associated with these traumatic events.[32]
It has been suggested that acetylcysteine may help people with Samter's triad by increasing levels of glutathione allowing faster breakdown of salicylates, although there is no evidence that it is of benefit.[60]
Small studies have shown acetylcysteine to be of benefit to people with blepharitis.[61] It has been shown to reduce ocular soreness caused by Sjögren's syndrome.[62]
It has been shown that N-acetylcysteine may protect the human cochlea from subclinical hearing loss caused by loud noises such as impulse noise.[63] In animal models, it reduced age-related hearing loss.
It has been shown effective in the treatment of Unverricht-Lundborg disease in an open trial in four patients. A marked decrease in myoclonus and some normalization of somatosensory evoked potentials with acetylcysteine treatment has been documented.[64][65]
Addiction to certain addictive drugs (e.g., cocaine, heroin, alcohol, and nicotine) is correlated with a persistent reduction in the expression of excitatory amino acid transporter 2 (EAAT2) in the nucleus accumbens (NAcc);[38] the reduced expression of EAAT2 in this region is implicated in addictive drug-seeking behavior.[38] In particular, the long-term dysregulation of glutamate neurotransmission in the NAcc of addicts is associated with an increase in vulnerability to relapse after re-exposure to the addictive drug or its associated drug cues.[38] Drugs that help to normalize the expression of EAAT2 in this region, such as N-acetylcysteine, have been proposed as an adjunct therapy for the treatment of addiction to cocaine, nicotine, alcohol, and other drugs.[38]
It is being tested for the reduction of hangover symptoms, but the clinical trial results are still being evaluated.[66]
A double-blind placebo controlled trial of 262 patients has shown NAC treatment was well-tolerated and resulted in a significant decrease in the frequency of influenza-like episodes, severity, and length of time confined to bed.[67]
Psychiatry[edit]
Acetylcysteine has been studied for a number of psychiatric disorders.[30][31][32] Several reviews found tentative evidence for N-acetylcysteine in the treatment of Alzheimer's disease, autism, bipolar disorder,[29] drug-induced neuropathy, major depressive disorder, obsessive-compulsive disorder, schizophrenia, specific drug addictions (cocaine), trichotillomania, excoriation disorder, and a certain form of epilepsy (progressive myoclonic).[30][31][33] Preliminary evidence showed efficacy in anxiety disorder, attention deficit hyperactivity disorder and mild traumatic brain injury although confirmatory studies are required.[33][68][69][36] Tentative evidence also supports use in cannabis use disorder.[70]

Bipolar disorder[edit]
In bipolar disorder, N-acetylcysteine has been repurposed as an augmentation strategy for depressive episodes in light of the possible role of inflammation in the pathogenesis of mood disorders. Nonetheless, meta-analytic evidence shows that add-on N-acetylcysteine was more effective than placebo only in reducing depression scales scores (low quality evidence), without positive effects on response and remission outcomes, limiting its possible role in clinical practice to date.[29]

COVID-19[edit]
NAC is being considered as a possible treatment for COVID-19.[71]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Stockley RA (2008). Chronic Obstructive Pulmonary Disease a Practical Guide to Management. Chichester: John Wiley & Sons. p. 750. ISBN 9780470755280. Archived from the original on 8 September 2017.

^ a b c d e f g h i j "Acetylcysteine". The American Society of Health-System Pharmacists. Archived from the original on 23 September 2015. Retrieved 22 August 2015.

^ "ACETADOTE (acetylcysteine) injection, solution [Cumberland Pharmaceuticals Inc.]". DailyMed. Cumberland Pharmaceuticals Inc. June 2013. Archived from the original on 13 January 2014. Retrieved 8 November 2013.

^ "L-Cysteine, N-acetyl- - Compound Summary". PubChem Compound. National Center for Biotechnology Information. 25 March 2005. Identification. Archived from the original on 12 January 2014. Retrieved 9 January 2012.

^ a b c "N-ACETYL-L-CYSTEINE Product Information" (PDF). Sigma. Sigma-aldrich. Archived from the original (PDF) on 11 June 2014. Retrieved 9 November 2014.

^ Talbott, Shawn M. (2012). A Guide to Understanding Dietary Supplements. Routledge. p. 469. ISBN 9781136805707. Archived from the original on 8 September 2017.

^ "Cysteine". University of Maryland Medical Center. Retrieved 23 June 2017. {{cite web}}: Check |archive-url= value (help)CS1 maint: url-status (link)

^ Sadowska, Anna M; Verbraecken, J; Darquennes, K; De Backer, WA (December 2006). "Role of N-acetylcysteine in the management of COPD". International Journal of Chronic Obstructive Pulmonary Disease. 1 (4): 425–434. doi:10.2147/copd.2006.1.4.425. ISSN 1176-9106. PMC 2707813. PMID 18044098.

^ Fischer J, Ganellin CR (2006). Analogue-Based Drug Discovery. Weinheim: Wiley-VCH. p. 544. ISBN 9783527607495. Archived from the original on 8 September 2017.

^ .mw-parser-output .citation{word-wrap:break-word}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}US patent 3091569, Aaron Leonard Sheffner, "Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus", published 1963-05-28, issued 1963-05-28,  assigned to Mead Johnson & Co 

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ Baker E (2014). Top 100 drugs : clinical pharmacology and practical prescribing. p. Acetylcysteine. ISBN 9780702055157. Archived from the original on 8 September 2017.

^ a b Green JL, Heard KJ, Reynolds KM, Albert D (May 2013). "Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis". The Western Journal of Emergency Medicine. 14 (3): 218–26. doi:10.5811/westjem.2012.4.6885. PMC 3656701. PMID 23687539.

^ a b c "Acetadote Package Insert" (PDF). FDA. Archived (PDF) from the original on 25 August 2013. Retrieved 19 April 2014.

^ Borgström L, Kågedal B, Paulsen O (1986). "Pharmacokinetics of N-acetylcysteine in man". European Journal of Clinical Pharmacology. 31 (2): 217–22. doi:10.1007/bf00606662. PMID 3803419. S2CID 41004554.

^ a b Dilger RN, Baker DH (July 2007). "Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine". Journal of Animal Science. 85 (7): 1712–8. doi:10.2527/jas.2006-835. PMID 17371789.

^ Kanter MZ (October 2006). "Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning". American Journal of Health-System Pharmacy. 63 (19): 1821–7. doi:10.2146/ajhp060050. PMID 16990628. S2CID 9209528.

^ Dawson AH, Henry DA, McEwen J (March 1989). "Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning". The Medical Journal of Australia. 150 (6): 329–31. doi:10.5694/j.1326-5377.1989.tb136496.x. PMID 2716644. S2CID 40296724.

^ Bailey B, McGuigan MA (June 1998). "Management of anaphylactoid reactions to intravenous N-acetylcysteine". Annals of Emergency Medicine. 31 (6): 710–5. doi:10.1016/S0196-0644(98)70229-X. PMID 9624310.

^ Schmidt LE, Dalhoff K (January 2001). "Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning". British Journal of Clinical Pharmacology. 51 (1): 87–91. doi:10.1046/j.1365-2125.2001.01305.x. PMC 2014432. PMID 11167669.

^ Lynch RM, Robertson R (January 2004). "Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study". Accident and Emergency Nursing. 12 (1): 10–5. doi:10.1016/j.aaen.2003.07.001. PMID 14700565.

^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.

^ Tam, J; Nash, EF; Ratjen, F; Tullis, E; Stephenson, A (12 July 2013). "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis" (PDF). The Cochrane Database of Systematic Reviews (7): CD007168. doi:10.1002/14651858.CD007168.pub3. PMC 8078644. PMID 23852992.

^ Grandjean EM, Berthet P, Ruffmann R, Leuenberger P (February 2000). "Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials". Clinical Therapeutics. 22 (2): 209–21. doi:10.1016/S0149-2918(00)88479-9. PMID 10743980.

^ Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR (August 2000). "The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review". The European Respiratory Journal. 16 (2): 253–62. doi:10.1034/j.1399-3003.2000.16b12.x. PMID 10968500.

^ Poole PJ, Black PN (May 2001). "Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review". BMJ. 322 (7297): 1271–4. doi:10.1136/bmj.322.7297.1271. PMC 31920. PMID 11375228.

^ Pistolesi, V; Regolisti, G; Morabito, S; Gandolfini, I; Corrado, S; Piotti, G; Fiaccadori, E (December 2018). "Contrast medium induced acute kidney injury: a narrative review". Journal of Nephrology. 31 (6): 797–812. doi:10.1007/s40620-018-0498-y. PMID 29802583. S2CID 44128861.

^ "Hemorrhagic Cystitis Treatment & Management: Approach Considerations, Clot Evacuation, Bladder Irrigation Agents". 5 December 2019. Retrieved 18 December 2019.

^ a b c d e Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, Carrà G (September 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.

^ a b c d e Dean O, Giorlando F, Berk M (March 2011). "N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action". Journal of Psychiatry & Neuroscience. 36 (2): 78–86. doi:10.1503/jpn.100057. PMC 3044191. PMID 21118657.

^ a b c d e f g h Berk M, Malhi GS, Gray LJ, Dean OM (March 2013). "The promise of N-acetylcysteine in neuropsychiatry". Trends in Pharmacological Sciences. 34 (3): 167–77. doi:10.1016/j.tips.2013.01.001. PMID 23369637.

^ a b c Bavarsad Shahripour R, Harrigan MR, Alexandrov AV (March 2014). "N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities". Brain and Behavior. 4 (2): 108–22. doi:10.1002/brb3.208. PMC 3967529. PMID 24683506.

^ a b c d e Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R (August 2015). "Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review". Neuroscience and Biobehavioral Reviews. 55: 294–321. doi:10.1016/j.neubiorev.2015.04.015. PMID 25957927.

^ Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS (June 2014). "The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial". The Journal of Clinical Psychiatry. 75 (6): 628–36. doi:10.4088/JCP.13m08454. PMID 25004186.

^ Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, Sarris J (April 2015). "N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review". Clinical Psychopharmacology and Neuroscience. 13 (1): 12–24. doi:10.9758/cpn.2015.13.1.12. PMC 4423164. PMID 25912534.

^ a b Samuni Y, Goldstein S, Dean OM, Berk M (August 2013). "The chemistry and biological activities of N-acetylcysteine". Biochimica et Biophysica Acta (BBA) - General Subjects. 1830 (8): 4117–29. doi:10.1016/j.bbagen.2013.04.016. hdl:11343/43874. PMID 23618697.

^ Minarini, A; Ferrari, S; Galletti, M; Giambalvo, N; Perrone, D; Rioli, G; Galeazzi, GM (2 November 2016). "N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects". Expert Opinion on Drug Metabolism & Toxicology. 13 (3): 279–292. doi:10.1080/17425255.2017.1251580. PMID 27766914. S2CID 20873065.

^ a b c d e f McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM (2014). "Potential role of N-acetylcysteine in the management of substance use disorders". CNS Drugs. 28 (2): 95–106. doi:10.1007/s40263-014-0142-x. PMC 4009342. PMID 24442756.

^ Buijtels PC, Petit PL (July 2005). "Comparison of NaOH-N-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens". Journal of Microbiological Methods. 62 (1): 83–8. doi:10.1016/j.mimet.2005.01.010. PMID 15823396.

^ Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J (February 2010). "N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus" (PDF). Biochemical Pharmacology. 79 (3): 413–20. doi:10.1016/j.bcp.2009.08.025. PMID 19732754.

^ Aslam S, Darouiche RO (September 2011). "Role of antibiofilm-antimicrobial agents in controlling device-related infections". The International Journal of Artificial Organs. 34 (9): 752–8. doi:10.5301/ijao.5000024. PMC 3251652. PMID 22094553.

^ Garrett CE, Prasad K (2004). "The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions". Advanced Synthesis & Catalysis. 346 (8): 889–900. doi:10.1002/adsc.200404071.

^ "Acetylcysteine", livertox.nih.gov, retrieved 26 April 2019

^ a b "Mucomyst Package Insert". Archived from the original on 21 April 2014. Retrieved 20 April 2014.

^ a b Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, Forbes MS, Macdonald T, Gaston B (September 2007). "S-nitrosothiols signal hypoxia-mimetic vascular pathology". The Journal of Clinical Investigation. 117 (9): 2592–601. doi:10.1172/JCI29444. PMC 1952618. PMID 17786245.

^ Hildebrandt W, Alexander S, Bärtsch P, Dröge W (March 2002). "Effect of N-acetyl-cysteine on the hypoxic ventilatory response and erythropoietin production: linkage between plasma thiol redox state and O(2) chemosensitivity". Blood. 99 (5): 1552–5. doi:10.1182/blood.V99.5.1552. PMID 11861267. S2CID 24375953.

^ Wang AL, Wang JP, Wang H, Chen YH, Zhao L, Wang LS, Wei W, Xu DX (March 2006). "A dual effect of N-acetylcysteine on acute ethanol-induced liver damage in mice". Hepatology Research. 34 (3): 199–206. doi:10.1016/j.hepres.2005.12.005. PMID 16439183.

^ "PRODUCT INFORMATION ACETADOTE® CONCENTRATED INJECTION" (PDF). TGA eBusiness Services. Phebra Pty Ltd. 16 January 2013. Archived from the original on 8 September 2017. Retrieved 8 November 2013.

^ Steullet, P.; Neijt, H.C.; Cuénod, M.; Do, K.Q. (2006). "Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia". Neuroscience. 137 (3): 807–819. doi:10.1016/j.neuroscience.2005.10.014. ISSN 0306-4522. PMID 16330153. S2CID 1417873.

^ a b Varga, V.; Jenei, Zs.; Janáky, R.; Saransaari, P.; Oja, S. S. (1997). "Glutathione Is an Endogenous Ligand of Rat Brain N-Methyl-D-Aspartate (NMDA) and 2-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate (AMPA) Receptors". Neurochemical Research. 22 (9): 1165–1171. doi:10.1023/A:1027377605054. ISSN 0364-3190. PMID 9251108. S2CID 24024090.

^ Oja, S (2000). "Modulation of glutamate receptor functions by glutathione". Neurochemistry International. 37 (2–3): 299–306. doi:10.1016/S0197-0186(00)00031-0. ISSN 0197-0186. PMID 10812215. S2CID 44380765.

^ Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuénod M, Buclin T, Do KQ (August 2008). "Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients". Neuropsychopharmacology. 33 (9): 2187–99. doi:10.1038/sj.npp.1301624. PMID 18004285.

^ Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (December 2008). "N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility". Expert Opinion on Biological Therapy. 8 (12): 1955–62. doi:10.1517/14728220802517901. PMID 18990082. S2CID 74736842.

^ Kupchik YM, Moussawi K, Tang XC, Wang X, Kalivas BC, Kolokithas R, Ogburn KB, Kalivas PW (June 2012). "The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine". Biological Psychiatry. 71 (11): 978–86. doi:10.1016/j.biopsych.2011.10.024. PMC 3340445. PMID 22137594.

^ "N-Acetyl-L-cysteine | C5H9NO3S - PubChem". Archived from the original on 16 August 2016. Retrieved 22 July 2016.

^ "Amazon confirms plans on removing NAC supplements".

^ "Amazon reportedly removes NAC-containing dietary supplements".

^ a b Head, Stewart I. (29 October 2017). "Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising results but with a weighty caveat". The Journal of Physiology. 595 (23): 7015. doi:10.1113/jp275232. ISSN 0022-3751. PMC 5709324. PMID 29034480.

^ Gu F, Chauhan V, Chauhan A (January 2015). "Glutathione redox imbalance in brain disorders". Current Opinion in Clinical Nutrition and Metabolic Care. 18 (1): 89–95. doi:10.1097/MCO.0000000000000134. PMID 25405315. S2CID 25333289.

^ Bachert C, Hörmann K, Mösges R, Rasp G, Riechelmann H, Müller R, Luckhaupt H, Stuck BA, Rudack C (March 2003). "An update on the diagnosis and treatment of sinusitis and nasal polyposis". Allergy. 58 (3): 176–91. doi:10.1034/j.1398-9995.2003.02172.x. PMID 12653791. S2CID 35319457.

^ Aitio ML (January 2006). "N-acetylcysteine -- passe-partout or much ado about nothing?". British Journal of Clinical Pharmacology. 61 (1): 5–15. doi:10.1111/j.1365-2125.2005.02523.x. PMC 1884975. PMID 16390346.

^ Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, Dick WC (September 1974). "Management of the dry eye in Sjogren's syndrome". The British Journal of Ophthalmology. 58 (9): 798–805. doi:10.1136/bjo.58.9.798. PMC 1215027. PMID 4433493.

^ Ann-Cathrine Lindblad et al. (November–December 2011). "The efficacy of N-acetylcysteine to protect the human cochlea from subclinical hearing loss caused by impulse noise: a controlled trial". Noise Health. 13 (55): 392–401. doi:10.4103/1463-1741.90293. PMID 22122955.

^ Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, Sisodiya S (November 2002). "N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects". Neurology. 59 (9): 1447–9. doi:10.1212/wnl.59.9.1447. PMID 12427904.

^ Ataxia with Identified Genetic and Biochemical Defects at eMedicine

^ d. o, Holly Stankewicz (10 September 2017). "Use of NAC in Alleviation of Hangover Symptoms - Study Results - ClinicalTrials.gov". clinicaltrials.gov.

^ De Flora, S.; Grassi, C.; Carati, L. (1 July 1997). "Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment". European Respiratory Journal. 10 (7): 1535–1541. doi:10.1183/09031936.97.10071535. PMID 9230243.

^ Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS (June 2014). "The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial". The Journal of Clinical Psychiatry. 75 (6): 628–36. doi:10.4088/JCP.13m08454. PMID 25004186.

^ Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, Sarris J (April 2015). "N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review". Clinical Psychopharmacology and Neuroscience. 13 (1): 12–24. doi:10.9758/cpn.2015.13.1.12. PMC 4423164. PMID 25912534.

^ Minarini, A; Ferrari, S; Galletti, M; Giambalvo, N; Perrone, D; Rioli, G; Galeazzi, GM (2 November 2016). "N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects". Expert Opinion on Drug Metabolism & Toxicology. 13 (3): 279–292. doi:10.1080/17425255.2017.1251580. PMID 27766914. S2CID 20873065.

^ "N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence".


External links[edit]
"Acetylcysteine". Drug Information Portal. U.S. National Library of Medicine.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteCough and cold preparations (R05)Expectorants
Althea root
Antimony pentasulfide
Creosote
Guaiacolsulfonate
Guaifenesin (+ oxomemazine)
Ipecacuanha (Syrup of ipecac)
Levoverbenone
Potassium iodide
Senega
Tyloxapol
Ammonium Chloride
Mucolytics
Acetylcysteine#
Ambroxol
Bromhexine
Carbocisteine
Domiodol
Dornase alfa
Eprazinone
Erdosteine
Letosteine
Mannitol
Mesna
Neltenexine
Sobrerol
Stepronin
Cough suppressantsOpium alkaloids,opioids,and derivatives
Acetyldihydrocodeine
Benzylmorphine
Butorphanol
Codeine#
Dextromethorphan
Dihydrocodeine
Dimemorfan
Droxypropine
Ethylmorphine
Heroin
Hydrocodone
Hydromorphone
Isoaminile
Laudanum
Levomethadone
Levopropoxyphene
Methadone
Nicocodeine
Nicodicodeine
Normethadone
Noscapine
Pholcodine
Thebacon
Tipepidine
Other
Alloclamide
Benzonatate
Benproperine
Bibenzonium bromide
Butamirate
Clobutinol
Clofedanol
Cloperastine
Diphenhydramine
Dibunate
Dimethoxanate
Dropropizine
Fedrilate
Fominoben
Glaucine
Levodropropizine
Meprotixol
Moguisteine
Morclofone
Nepinalone
Oxolamine
Oxeladin
Pentoxyverine
Pipazetate
Prenoxdiazine
Piperidione
Zipeprol

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteAntioxidantsFood antioxidants
6-Hydroxymelatonin
Acetyl-L-carnitine (ALCAR)
Alpha-lipoic acid (ALA)
Ascorbic acid (vitamin C)
Carotenoids (vitamin A)
Curcumin
Edaravone
Polyphenols
Glutathione
Hydroxytyrosol
L-carnitine
Ladostigil
Melatonin
Mofegiline
N-Acetylcysteine (NAC)
N-Acetylserotonin (NAS)
Oleocanthal
Oleuropein
Rasagiline
Resveratrol
Selegiline
Selenium
Tocopherols (vitamin E)
Tocotrienols (vitamin E)
Tyrosol
Ubiquinone (coenzyme Q)
Uric acid
Fuel antioxidants
Butylated hydroxyanisole
Butylated hydroxytoluene
2,6-Di-tert-butylphenol
1,2-Diaminopropane
2,4-Dimethyl-6-tert-butylphenol
Ethylenediamine
Measurements
Folin method
ORAC
TEAC
FRAP

vteAntidotes (V03AB)Nervous systemAlcohol intoxication
Metadoxine, Thiamine
Barbiturate overdose
Bemegride
Ethamivan
Benzodiazepine overdose
Cyprodenate
Flumazenil
GHB overdose
Physostigmine
SCH-50911
Nerve agent / Organophosphate poisoning
Atropine#
Biperiden
Diazepam#
Oximes
Obidoxime
Pralidoxime
see also: Cholinesterase
Opioid overdose
Diprenorphine
Doxapram
Nalmefene
Nalorphine
Naloxone#
Naltrexone
Reversal of neuromuscular blockade
Sugammadex
Circulatory systemBeta blocker
Glucagon
Digoxin toxicity
Digoxin immune fab
Anticoagulants
against direct Xa inhibitors (Andexanet alfa)
against heparin (Protamine#)
OtherArsenic poisoning
Dimercaprol#
Succimer
Cyanide poisoning
4-Dimethylaminophenol
Hydroxocobalamin
nitrite
Amyl nitrite
Sodium nitrite#
Sodium thiosulfate#
Hydrofluoric acid
Calcium gluconate#
Methanol / Ethylene glycol poisoning
Primary alcohols: Ethanol
Fomepizole
Paracetamol toxicity (Acetaminophen)
Acetylcysteine#
Glutathione
Methionine#
Toxic metals (cadmium
lead
mercury
thallium)
Dimercaprol#
Edetates
Prussian blue#
Other
iodine-131
Potassium iodide
Methylthioninium chloride#
oxidizing agent
Potassium permanganate
Prednisolone/promethazine
Emetic
Copper sulfate
Ipecacuanha
Syrup of ipecac

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

Glutamate receptor modulators
vteIonotropic glutamate receptor modulatorsAMPAR
Agonists: Main site agonists: 5-Fluorowillardiine
Acromelic acid (acromelate)
AMPA
BOAA
Domoic acid
Glutamate
Ibotenic acid
Proline
Quisqualic acid
Willardiine; Positive allosteric modulators: Aniracetam
BIIB-104 (PF-04958242)
Cyclothiazide
CX-516
CX-546
CX-614
Farampator (CX-691, ORG-24448)
CX-717
CX-1739
CX-1942
Diazoxide
Hydrochlorothiazide (HCTZ)
IDRA-21
LY-392098
LY-395153
LY-404187
LY-451646
LY-503430
Mibampator (LY-451395)
Nooglutyl
ORG-26576
Oxiracetam
PEPA
Piracetam
Pramiracetam
S-18986
Tulrampator (S-47445, CX-1632)
Antagonists: ACEA-1011
ATPO
Becampanel
Caroverine
CNQX
Dasolampanel
DNQX
Fanapanel (MPQX)
GAMS
Kaitocephalin
Kynurenic acid
Kynurenine
Licostinel (ACEA-1021)
NBQX
PNQX
Selurampanel
Tezampanel
Theanine
Topiramate
YM90K
Zonampanel; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
Cyclopropane
Enflurane
Ethanol (alcohol)
Evans blue
GYKI-52466
GYKI-53655
Halothane
Irampanel
Isoflurane
Perampanel
Pregnenolone sulfate
Sevoflurane
Talampanel; Unknown/unsorted antagonists: Minocycline
KAR
Agonists: Main site agonists: 5-Bromowillardiine
5-Iodowillardiine
Acromelic acid (acromelate)
AMPA
ATPA
Domoic acid
Glutamate
Ibotenic acid
Kainic acid
LY-339434
Proline
Quisqualic acid
SYM-2081; Positive allosteric modulators: Cyclothiazide
Diazoxide
Enflurane
Halothane
Isoflurane
Antagonists: ACEA-1011
CNQX
Dasolampanel
DNQX
GAMS
Kaitocephalin
Kynurenic acid
Licostinel (ACEA-1021)
LY-382884
NBQX
NS102
Selurampanel
Tezampanel
Theanine
Topiramate
UBP-302; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
Enflurane
Ethanol (alcohol)
Evans blue
NS-3763
Pregnenolone sulfate
NMDAR
Agonists: Main site agonists: AMAA
Aspartate
Glutamate
Homocysteic acid (L-HCA)
Homoquinolinic acid
Ibotenic acid
NMDA
Proline
Quinolinic acid
Tetrazolylglycine
Theanine; Glycine site agonists: β-Fluoro-D-alanine
ACBD
ACC (ACPC)
ACPD
AK-51
Apimostinel (NRX-1074)
B6B21
CCG
D-Alanine
D-Cycloserine
D-Serine
DHPG
Dimethylglycine
Glycine
HA-966
L-687414
L-Alanine
L-Serine
Milacemide
Neboglamine (nebostinel)
Rapastinel (GLYX-13)
Sarcosine; Polyamine site agonists: Neomycin
Spermidine
Spermine; Other positive allosteric modulators: 24S-Hydroxycholesterol
DHEA (prasterone)
DHEA sulfate (prasterone sulfate)
Epipregnanolone sulfate
Plazinemdor
Pregnenolone sulfate
SAGE-201
SAGE-301
SAGE-718
Antagonists: Competitive antagonists: AP5 (APV)
AP7
CGP-37849
CGP-39551
CGP-39653
CGP-40116
CGS-19755
CPP
Kaitocephalin
LY-233053
LY-235959
LY-274614
MDL-100453
Midafotel (d-CPPene)
NPC-12626
NPC-17742
PBPD
PEAQX
Perzinfotel
PPDA
SDZ-220581
Selfotel; Glycine site antagonists: 4-Cl-KYN (AV-101)
5,7-DCKA
7-CKA
ACC
ACEA-1011
ACEA-1328
Apimostinel (NRX-1074)
AV-101
Carisoprodol
CGP-39653
CNQX
D-Cycloserine
DNQX
Felbamate
Gavestinel
GV-196771
Harkoseride
Kynurenic acid
Kynurenine
L-689560
L-701324
Licostinel (ACEA-1021)
LU-73068
MDL-105519
Meprobamate
MRZ 2/576
PNQX
Rapastinel (GLYX-13)
ZD-9379; Polyamine site antagonists: Arcaine
Co 101676
Diaminopropane
Diethylenetriamine
Huperzine A
Putrescine; Uncompetitive pore blockers (mostly dizocilpine site): 2-MDP
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
8A-PDHQ
18-MC
α-Endopsychosin
Alaproclate
Alazocine (SKF-10047)
Amantadine
Aptiganel
Argiotoxin-636
Arketamine
ARL-12495
ARL-15896-AR
ARL-16247
Budipine
Coronaridine
Delucemine (NPS-1506)
Dexoxadrol
Dextrallorphan
Dextromethadone
Dextromethorphan
Dextrorphan
Dieticyclidine
Diphenidine
Dizocilpine
Ephenidine
Esketamine
Etoxadrol
Eticyclidine
Fluorolintane
Gacyclidine
Ibogaine
Ibogamine
Indantadol
Ketamine
Ketobemidone
Lanicemine
Levomethadone
Levomethorphan
Levomilnacipran
Levorphanol
Loperamide
Memantine
Methadone
Methorphan
Methoxetamine
Methoxphenidine
Milnacipran
Morphanol
NEFA
Neramexane
Nitromemantine
Noribogaine
Norketamine
Orphenadrine
PCPr
PD-137889
Pethidine (meperidine)
Phencyclamine
Phencyclidine
Propoxyphene
Remacemide
Rhynchophylline
Rimantadine
Rolicyclidine
Sabeluzole
Tabernanthine
Tenocyclidine
Tiletamine
Tramadol; Ifenprodil (NR2B) site antagonists:
Besonprodil
Buphenine (nylidrin)
CO-101244 (PD-174494)
Eliprodil
Haloperidol
Isoxsuprine
Radiprodil (RGH-896)
Rislenemdaz (CERC-301, MK-0657)
Ro 8-4304
Ro 25-6981
Safaprodil
Traxoprodil (CP-101606); NR2A-selective antagonists: MPX-004
MPX-007
TCN-201
TCN-213; Cations: Hydrogen
Magnesium
Zinc; Alcohols/volatile anesthetics/related: Benzene
Butane
Chloroform
Cyclopropane
Desflurane
Diethyl ether
Enflurane
Ethanol (alcohol)
Halothane
Hexanol
Isoflurane
Methoxyflurane
Nitrous oxide
Octanol
Sevoflurane
Toluene
Trichloroethane
Trichloroethanol
Trichloroethylene
Urethane
Xenon
Xylene; Unknown/unsorted antagonists: ARR-15896
Bumetanide
Caroverine
Conantokin
D-αAA
Dexanabinol
Flufenamic acid
Flupirtine
FPL-12495
FR-115427
Furosemide
Hodgkinsine
Ipenoxazone (MLV-6976)
MDL-27266
Metaphit
Minocycline
MPEP
Niflumic acid
Pentamidine
Pentamidine isethionate
Piretanide
Psychotridine
Transcrocetin (saffron)
Unsorted: Allosteric modulators: AGN-241751

See also: Receptor/signaling modulators
Metabotropic glutamate receptor modulators
Glutamate metabolism/transport modulators

vteMetabotropic glutamate receptor modulatorsGroup ImGluR1
Agonists: ACPD
DHPG
Glutamate
Ibotenic acid
Quisqualic acid
Ro01-6128
Ro67-4853
Ro67-7476
VU-71
Theanine
Antagonists: BAY 36-7620
CPCCOEt
Cyclothiazide
LY-367,385
LY-456,236
MCPG
NPS-2390
mGluR5
Agonists: ACPD
ADX-47273
CDPPB
CHPG
DFB
DHPG
Glutamate
Ibotenic acid
Quisqualic acid
VU-1545
Antagonists: CTEP
DMeOB
LY-344,545
Mavoglurant
MCPG
NPS-2390
Remeglurant
SIB-1757
SIB-1893; Negative allosteric modulators: Basimglurant
Dipraglurant
Fenobam
GRN-529
MPEP
MTEP
Raseglurant
Group IImGluR2
Agonists: BINA
CBiPES
DCG-IV
Eglumegad
Glutamate
Ibotenic acid
LY-379,268
LY-404,039 (pomaglumetad)
LY-487,379
LY-566,332
MGS-0028
Pomaglumetad methionil (LY-2140023)
Talaglumetad; Positive allosteric modulators: JNJ-40411813 (ADX-71149)
Antagonists: APICA
CECXG
EGLU
HYDIA
LY-307,452
LY-341,495
MCPG
MGS-0039
PCCG-4; Negative allosteric modulators: Decoglurant
RO4491533
mGluR3
Agonists: CBiPES
DCG-IV
Eglumegad
Glutamate
Ibotenic acid
LY-379,268
LY-404,039 (pomaglumetad)
LY-487,379
MGS-0028
Pomaglumetad methionil (LY-2140023)
Talaglumetad
Antagonists: APICA
CECXG
EGLU
HYDIA
LY-307,452
LY-341,495
MCPG
MGS-0039; Negative allosteric modulators: Decoglurant
RO4491533
Group IIImGluR4
Agonists: Glutamate
L-AP4
PHCCC
VU-001,171
VU-0155,041; Positive allosteric modulators: Foliglurax
MPEP
Antagonists: CPPG
MAP4
MPPG
MSOP
MTPG
UBP-1112
mGluR6
Agonists: Glutamate
L-AP4
Antagonists: CPPG
MAP4
MPPG
MSOP
MTPG
UBP-1112
mGluR7
Agonists: AMN082
Glutamate
L-AP4
Antagonists: CPPG
MAP4
MMPIP
MPPG
MSOP
MTPG
UBP-1112
mGluR8
Agonists: DCPG
Glutamate
L-AP4
Antagonists: CPPG
MAP4
MPPG
MSOP
MTPG
UBP-1112
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators
.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





